Arctic Bioscience AS (ABS.OL) Q3 2024 Earnings Report

Arctic Bioscience AS (ABS.OL) reported a tangible topline expansion in Q3 2024 with revenue of NOK 13.60 million, up 85.35% year over year and 58.10% quarter over quarter, signaling growing demand for its nutraceutical bulk ingredients and early-stage revenue streams. Despite the revenue lift, the company remains unprofitable at the operating and net levels, driven by persistent investment in R&D and significant other operating expenses. Gross profit for the quarter was NOK 3.61 million, delivering a gross margin of 26.54%, but operating expenses totalled NOK 15.41 million, producing an EBITDA of NOK -11.08 million and an operating income of NOK -11.80 million. Net income stood at NOK -12.21 million with an EPS of -0.48, underscoring the development-stage cost structure. Cash burn persisted, with cash flow from operations at NOK -9.88 million and free cash flow at NOK -35.21 million after capex of NOK -25.33 million, leaving a modest cash balance of NOK 3.28 million at period end. The balance sheet shows a prudent equity cushion (NOK 210.73 million) and manageable gross leverage (total debt NOK 21.71 million; net debt NOK 18.43 million) but a current ratio below 1.0 (0.86) and a quiet liquidity profile, highlighting near-term funding considerations. The four-quarter trend indicates a favorable revenue trajectory entering late 2024, yet profitability hinges on pipeline progress, licensing/partnerships, and potential monetization of nutraceuticals. The company does not publish explicit forward guidance for QQ4 2024 in the presented data, so investors should monitor HRO350 development timelines, partner discussions, and burn rate for runway adequacy.